These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7699426)

  • 1. In vitro antibacterial activity of the new quinolone Bay y3118 against clinical isolates.
    Ravizzola G; Pizzi R; Pirali F; Turano A
    J Chemother; 1994 Dec; 6(6):392-8. PubMed ID: 7699426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.
    Piddock LJ; Marshall AJ; Jin YF
    Antimicrob Agents Chemother; 1994 Mar; 38(3):422-7. PubMed ID: 8203834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP; Hoogkamp-Korstanje JA
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.
    Bremm KD; Petersen U; Metzger KG; Endermann R
    Chemotherapy; 1992; 38(6):376-87. PubMed ID: 1288961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Gooch G; Ho DH; Bodey GP
    J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of Bay Y3118 against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of in vitro activity of trovafloxacin against gram-positive and gram-negative organisms with quinolones and beta-lactam antimicrobial agents.
    Dembry LM; Roberts JC; Schock KD; Marino SP; Farrel PA; Andriole VT
    Diagn Microbiol Infect Dis; 1998 May; 31(1):301-11. PubMed ID: 9597391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
    Giamarellou H; Voutsinas D; Xirouchaki E
    J Chemother; 1992 Feb; 4(1):12-5. PubMed ID: 1328554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.
    Marshall SA; Jones RN
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2747-53. PubMed ID: 8109948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.
    Qadri SM; Ueno Y; Postle G; Tullo D; San Pedro J
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):372-7. PubMed ID: 8394816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci.
    Spangler SK; Jacobs MR; Appelbaum PC
    Eur J Clin Microbiol Infect Dis; 1993 Dec; 12(12):965-7. PubMed ID: 8187796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.
    Boswell FJ; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1377-9. PubMed ID: 9174203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.